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Summary  The  epidemiology  of  infective  endocarditis  is  changing  rapidly  due  to  the  emer-
gence of  resistant  microorganisms,  the  indiscriminate  use  of  antibiotics,  and  an  increase  in  the
implantation  of  cardiovascular  devices  including  percutaneous  valves.  Percutaneous  pulmonary
valve implantation  has  achieved  standard  of  care  for  the  management  of  certain  patients  with
right ventricular  outﬂow  tract  dysfunction.  With  its  expanding  use,  several  cases  of  early  and
delayed infective  endocarditis  with  higher  morbidity  and  mortality  rates  have  been  reported.
This review  summarizes  the  trends  in  percutaneous  pulmonary  valve  infective  endocarditis,
postulates  proposed  mechanisms,  and  elaborates  on  the  prevention  and  management  of  this
unique and  potentially  fatal  complication.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
Abbreviations: CHD, congenital heart disease; IE, infective endocarditis; PPV, percutaneous pulmonary valve; PPVI, percutaneous
pulmonary valve implantation; RVOT, right ventricular outﬂow tract.
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Résumé  L’épidémiologie  des  endocardites  infectieuses  change  rapidement  en  raison  de
l’émergence  de  micro-organismes  résistants,  à  l’utilisation  large  des  antibiotiques,  et  à
l’augmentation  des  implants  cardiovasculaires.  L’implantation  de  valves  percutanées  fait  désor-
mais partie  de  la  prise  en  charge  conventionnelle  des  patients  avec  dysfonction  de  la  voie
d’éjection  droite.  Avec  son  expansion  rapide,  plusieurs  cas  d’endocardites  infectieuses  préco-
ces et  tardives  ont  été  rapportés  avec  un  risque  accru  de  morbi-mortalité.  Cette  revue  résume
les connaissances  actuelles  sur  le  sujet,  propose  des  mécanismes  physiopathologiques  et  éla-
bore des  conduites  à  tenir  pour  prévenir  et  traiter  cette  complication  unique  et  potentiellement
fatale.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ercutaneous  pulmonary  valve  implantation  (PPVI)  (Melody®
alve;  Medtronic,  Minneapolis,  MN,  USA)  has  become  estab-
ished  as  a  valuable  treatment  option  for  patients  with  right
entricular  outﬂow  tract  (RVOT)  dysfunction  since  its  clin-
cal  introduction  in  2000  [1—4].  Excellent  early,  mid-term
nd  even  long-term  success  rates,  with  improvements  in
unctional  status,  peak  exercise  capacity  and  ventricular
unction,  have  been  reported  since  then  [5—12].  Unfortu-
ately,  because  of  factors  that  are  not  clearly  understood,
everal  cases  of  early  and  delayed  percutaneous  pulmonary
alve  infective  endocarditis  (PPV  IE)  have  been  reported.  IE
s  a  burden  in  the  congenital  heart  disease  (CHD)  popula-
ion,  particularly  in  patients  with  prosthetic  valves  in  whom
iagnosis  is  more  difﬁcult,  prognosis  is  worse  and  the  need
or  surgery  is  more  frequent  compared  with  CHD  patients
ith  native  valves.  Around  half  of  the  patients  with  CHD-
ssociated  IE  develop  severe  episode-related  complications
nd  the  mortality  rate  for  surgery  for  IE  is  very  high  (40—50%)
13—15].  In  this  review  article,  we  summarize  the  trends  in
PV  IE,  postulate  proposed  mechanisms,  and  elaborate  on
he  prevention  and  management  of  this  unique  and  poten-
ially  fatal  complication.
linical presentation and diagnosis
E  is  a  clinical  diagnosis  and  requires  a  high  index  of  sus-
icion,  especially  in  the  CHD  population,  as  patients  may
resent  with  non-speciﬁc  symptoms.  The  Duke  criteria  for
he  diagnosis  and  management  of  IE  were  initially  drafted  in
994;  they  were  later  modiﬁed  in  2002  to  include  echocar-
iography  criteria,  and  again  in  2007  for  optimal  clinical
se.  The  two  major  clinical  criteria  are  abnormal  blood  cul-
ures  and  evidence  of  endocardial  involvement.  The  ﬁve
inor  clinical  criteria  are  a  predisposition  to  IE,  a  fever
f  >  38 ◦C,  vascular  phenomena,  immunological  phenomena
r  microbiological  evidence  of  IE  not  meeting  major  crite-
ia.  Requirements  for  a  clinical  diagnosis  of  IE  are:  two
ajor  clinical  criteria;  one  major  and  three  minor  clini-
al  criteria;  or  ﬁve  minor  clinical  criteria  [16—18].  Although
hese  criteria  are  still  used  universally  for  IE,  the  patient
haracteristics,  timing  and  presentation  of  PPV  IE  are  quite
ﬁ
o
d
(omplex,  and  one  may  have  to  keep  a  high  index  of  suspi-
ion  in  such  patients.  It  is  important  to  note  that  the  clinical
resentation  with  atypical  organisms,  such  as  Coxiella  bur-
etii  endovascular  infection,  is  usually  insidious,  lacks  the
ypical  features  of  bacterial  endocarditis  and  often  results
n  delayed  diagnosis.  Patients  are  often  afebrile  and  vege-
ations  are  usually  absent  or  small  [19,20].
Deﬁnitive  IE  is  diagnosed  based  on  modiﬁed  Duke  crite-
ia,  although  in  patients  with  prosthetic  or  Melody  valves,
rue  valve  involvement  may  be  difﬁcult  to  determine  with
 high  degree  of  certainty,  because  of  the  acoustic  shadow-
ng  artefacts  from  the  prosthesis  and  the  unusual  anatomy
f  the  RVOT.  Transoesophageal  echocardiography  might  be
eeded.  However,  the  anterior  position  of  the  RVOT  makes
ts  visualization  very  difﬁcult  and  the  result  is  not  always
nconclusive.  An  increase  in  RVOT  gradient  from  postpro-
edure  echocardiogram  to  hospital  admission  is  present
n  most  patients  with  IE.  The  Duke  criteria  should  be
odiﬁed  for  this  particular  substrate  (i.e.  PPVI)  because,
n  our  opinion,  any  degree  of  increase  of  RVOT  gradient
unexplained  by  a  structural  complication,  such  as  stent
racture)  demonstrates  the  valvular  involvement  and  should
e  considered  as  a  major  criterion  similar  to  new  onset  of
ulmonary  regurgitation,  unless  proved  otherwise.  Based
n  these  features,  blood  stream  infection  with  a  rise  in
VOT  gradient  may  be  reclassiﬁed  as  deﬁnitive  endocarditis.
his  criterion  alone  may  very  well  explain  the  differ-
nce  noted  in  the  incidence  of  PPV  IE  between  reported
tudies.  Some  other  diagnostic  tools  may  be  helpful,
uch  as  intracardiac  echocardiography,  three-dimensional
chocardiography  or  positron  emission  tomography.  Positron
mission  tomography-computed  tomography  fusion  imaging
s  a  good  diagnostic  tool  in  case  of  difﬁculties  in  assessing
ot  spots  and  slow  mouldering  cardiac  involvement.
ncidence
everal  types  of  presentations  and  risk  factors  have  been
eported.  The  ﬁrst  series  in  2008  by  Lurz  et  al.  [21]  reported
ve  cases  of  PPV  IE  out  of  155  patients  with  an  age  range
f  7—71  years.  The  possible  risk  factors  reported  included
ental  treatment  (n  =  1),  septic  wound  after  arm  trauma
n  = 1),  reactivation  of  previously  treated  fungal  infection
617
Figure 1. Explanted specimen of right ventricular outﬂow tract
with Melody® valve, showing large ﬂeshy vegetations on the melody
valve, with signiﬁcant narrowing of the pulmonary oriﬁce.
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(n  =  1)  and  previous  history  of  medically  treated  IE  before
PPVI  (n  =  2)  [21].  Subsequently,  there  have  been  several
anecdotal  reports  of  PPV  IE.  Our  group  published  a  case
series  on  four  PPVI-related  IE  cases  involving  Streptococ-
cus  sanguis  (n  =  2),  Streptococcus  mitis  and  Staphylococcus
epidermidis.  Strikingly,  three  of  these  had  a  history  of
abrupt  aspirin  discontinuation.  Two  of  the  four  patients
died:  one  patient  (with  S.  epidermidis) died  on  the  day  of
presentation,  with  heart  failure  and  ventricular  ﬁbrillation;
and  the  other  (with  S.  sanguis)  died  of  multiorgan  fail-
ure  following  emergency  surgery  [22].  Subsequently,  Buber
et  al.  [23]  reported  on  14  subjects  who  developed  blood-
stream  infection,  four  of  them  with  deﬁnite  PPV  IE.  There
were  two  deaths  with  methicillin-resistant  Staphylococcus
aureus  bacteraemia  without  valve  involvement.  All  of  these
patients  had  recent  onset  of  obstructive  RVOT  dysfunction
before  PPV  IE.  Male  sex,  previous  IE,  high  number  of  stents
and  altered  RVOT  anatomy  were  identiﬁed  as  important  risk
factors.  Only  one  of  the  four  patients  with  documented  valve
involvement  underwent  surgical  valve  replacement.  A  more
recent  report  combining  the  results  of  three  manufacturer-
sponsored  prospective  North  American  and  European  studies
showed  that  16  of  311  patients  were  diagnosed  with  def-
inite  or  presumed  IE,  including  six  who  met  their  criteria
for  PPV  IE.  One  patient  with  valve-related  IE  died  after  bio-
prosthesis  explantation  and  multiple  complications.  Another
patient  died  with  severe  haemoptysis,  3  weeks  after  a
second  PPVI  for  progressive  pulmonary  stenosis.  Only  four
patients  required  Melody  valve  replacement  and  two  had
a  second  PPVI.  Two  subjects  presented  with  recurrent  IE,
1.6  and  2.7  years  after  the  initial  diagnosis.  One  of  the  two
patients  had  a  second  PPVI  for  stent  fracture-related  pul-
monary  stenosis  after  antibiotic  treatment  for  the  initial  IE
episode,  and  the  other  had  vegetation  at  initial  diagnosis
but  received  non-surgical  treatment  [24].  Cheung  et  al.  [25]
reported  six  cases  of  PPV  IE,  and  demonstrated  the  unique
utility  of  intracardiac  echocardiography  for  identifying  small
and  subtle  vegetations.  The  most  recent  report  by  Villafane
et  al.  [26]  described  four  paediatric  patients  with  PPV  IE:
two  had  documented  vegetations;  three  showed  worsen-
ing  pulmonary  stenosis  at  the  time  of  presentation;  three
underwent  surgical  valve  replacement  with  no  deaths.
It  is  interesting  to  note  that  there  is  no  speciﬁc
microbiology  pattern  of  Melody  valve  involvement.  Most
organisms,  from  cutaneous  commensals  to  pathogens
commonly  encountered  in  IE,  have  been  reported.  The  annu-
alized  rate  of  ﬁrst  episode  of  valve-related  IE  is  0.88%  per
patient-year.  None  of  the  patients  seen  in  our  institution  or
reported  in  the  literature  showed  any  septic  emboli  to  the
pulmonary  circulation.  Table  1  shows  the  various  studies  and
reports  in  the  literature  with  Melody  valve  IE.
Vegetations
There  are  very  few  reports  providing  in-depth  macroscopic
and  microscopic  details  of  vegetations.  We  reported  large,
ﬂeshy,  sessile,  loosely  attached  and  easily  retrievable  veg-
etations  on  the  Melody  valve.  The  vegetations  appeared
glistening  pink,  ﬁlling  the  cusps  and  reducing  the  pulmonary
oriﬁce  opening  to  a  pinhole  (Fig.  1).  The  underlying  leaﬂets
showed  no  signs  of  destruction  or  evidence  of  long-standing
infection,  and  appeared  normal  (Fig.  2)  [22].  A  few  other
7
i
w
gigure 2. The underlying leaﬂets of the Melody® valve are seen
s glistening and transparent with no signs of destruction.
eports  showed  similar  vegetations  on  macroscopic  exami-
ation  [27,28].  Histological  examination  showed  voluminous
brin  strands  with  no  microorganisms.  Importantly,  the
ulk  constituted  amorphous  material  was  mostly  thrombus
Fig.  3) [22]. It  is  almost  certain  from  the  available  literature
hat  none  of  the  cases  reported  so  far  represents  acceler-
ted  degeneration  of  the  bioprosthetic  valve  and  none  had
issue  failure  as  the  cause  of  IE.
nfective endocarditis in surgically
epaired right ventricular outﬂow tract
ersus percutaneous valves
wo  large  surgical  series  of  165  and  193  Contegra® conduits
Medtronic,  Minneapolis,  MN,  USA)  during  4.2—4.6  years  of
ollow-up  reported  six  cases  of  IE  [29,30].  Seven  cases  of  IE
ere  reported  by  Lee  et  al.  [31]  out  of  181  surgical  implan-
ations  of  bioprosthetic  valves  during  a  mean  follow-up  of
.3  years.  A  risk  comparison  between  PPVI  and  surgically
mplanted  bioprosthetic  valve  was  not  performed,  as  that
as  not  the  primary  objective  of  these  three  large  sur-
ical  series  and  also  due  to  discordance  in  the  timing  of
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Table  1  Melody  valve  endocarditis:  literature  review.
Reference  Year  of
publication
PPV  IE
cases/total
cases
Patient  age
(years)
PPVI  to  IE
interval
(months)
Pathogen  Proposed  major  risk
factors/trigger
Direct  valve
involvement
Mode  of
treatment
Outcomes
of  IE
Lurz  et  al.  [21]  2008  5/155  21  (7—71)  1.9—23.2  Staph  aureus;
Strep  aurelius;
Candida  albicans
Unprotected  dental
treatment  (n  =  1);
reactivation  of
previously-treated
fungal  infection
(n  =  1);  septic
wound  after  arm
trauma  (n  =  1);  prior
IE  (n  =  2)
ND  Surgery
(n  =  3);
medical
(n  =  2)
No  deaths
Eicken  et  al.  [47]  2011  1/102  21.5
(16—30)
6 Staph  aureus  ND  1  Surgery
(n  =  1)
No  deaths
Atamanyuk  et  al.
[28]
2011  1  15  65  Bartonella
henselae
Paravalvular  leak  1  Surgery
(n  =  1)
No  deaths
Roberts  et  al.
[49]
2011  1/15a 9  2  ND  ND  1  Surgery  No  deaths
Patel  et  al.  [22]  2012  4  (11—26)  3—28  Strep  sanguis
(n  =  2);  Strep
mitis; Staph
epidermidis
Abrupt
discontinuation  of
aspirin;  inherent  to
bovine  tissue;
residual  gradient
4  Surgery
(n  =  3,
including
one  with
emergency
RVOT  stent)
Two  deaths
Alsouﬁ  et  al.  [27]  2012  1  16  2.5  Aspergillus  Thrombus;  stenosis  1  Surgery
(n  =  1)
No  deaths
Bhat  et  al.  [45]  2012  1  19  4  Staph  aureus  ND  1  Surgery
(n  =  1)
No  deaths
Gillespie  et  al.
[48]
2012  3
(conﬁrmed
in  2)/104
26 (3—63)  13,  18  ND  2  Surgery
(n  =  2)
No  deaths
Butera  et  al.  [46]  2013  2/63  24  (11—65)  2—3  Staph  aureus  Disregarded  IE
prophylaxis
2  Surgery
(n  =  2)
No  deaths
Buber  et  al.  [23]  2013  14  BSI  (4
PPV  IE)/147
19  (3—59)  1—56  Strep  (50%);
Staph  (43%);
Haemophilus  (7%)
High  risk  of
systemic  bacterial
infections  with
male  sex;  previous
endocarditis
events;  high
number  of  stents  at
the  RVOT;  altered
RVOT  anatomy
4 Surgery
(n  =  1);
medical
(n  =  3)
No  deaths
in
conﬁrmed
IE
M
elody
 valve
 endocarditis
 
619
Table  1  (Continued)
Reference Year  of
publication
PPV  IE
cases/total
cases
Patient  age
(years)
PPVI  to  IE
interval
(months)
Pathogen Proposed  major  risk
factors/trigger
Direct  valve
involvement
Mode  of
treatment
Outcomes
of  IE
McElhinney  et  al.
[24]
2013  16  (6  PPV
IE)/311
21  (11—41) 1.7—56 Strep;  Staph;
Moraxella
catarrhalis
Prior  IE;  invasive
procedure;  bleeding
oral  ulcer;  IVDU;
high  pre-  and
postimplantation
gradients
4  Surgery
(n  =  4)
Two  deaths
Cheung  et  al.  [25] 2013  6/43  25  (6—67)  Strep  (n  =  2);
Staph  aureus
(n  =  2);  Staph
epidermidis;
Staph  gordonii
ND 2  Surgery
(n  =  2)
One  death
Villafane  et  al.
[26]
2014  4/143  11—20 1.7—16 Strep  viridans;
Strep  sanguis;
Staph  aureus;
Corynebacterium
Tattoo 3  Surgery
(n  =  3)
No  deaths
BSI: blood stream infection; IVDU: intravenous drug user; ND: no data/description; PPVI: percutaneous pulmonary valve implantation; PPV IE: percutaneous pulmonary valve infective
endocarditis; RVOT: right ventricular outﬂow tract; Staph: Staphylococcus;  Strep: Streptococcus.
a Melody® valve in tricuspid position.
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oigure 3. Microscopic examination of the vegetations, showing
redominant amorphous material composed of thrombus.
ead-to-head  comparisons.  There  are  several  reports  doc-
menting  an  increased  incidence  of  IE  with  bovine  conduits
32—38].  Analysis  of  registry  data  showed  a  higher  incidence
f  IE  in  the  Melody  valve  group  compared  with  in  the  surgical
roup  in  our  own  institution.
Between  January  2000  and  June  2013,  485  right  ventricle-
o-pulmonary  artery  conduit  implantations  (surgical  group)
nd  93  percutaneous  Melody  valves  implantations  (PPVI
roup)  were  carried  out  in  our  institution.  The  rates
f  IE  were  5.98  ±  2.11%  (surgical  group)  and  8.6  ±  5.7%
PPVI  group)  (P  =  0.34).  The  incidences  of  IE  in  the  various
VOT  conduits  were  different:  2.6%  in  homografts,  9.1%  in
ontegra  conduits  and  3.7%  in  bioprostheses  (excluding  Con-
egra).  The  incidence  of  IE  was  higher  in  the  patients  with
ontegra  conduits  compared  with  in  patients  with  homo-
rafts  (P  =  0.0245)  or  homografts  and  other  bioprostheses
P  =  0.0042).  During  the  study  period  when  both  techniques
ere  available  (2009—2013),  the  person-time  incidence
ates  of  IE  were  1.2  and  3.9  cases  per  100  person-years  in
he  surgical  and  PPVI  groups,  respectively  (P  =  0.03).  Clinical
resentations  and  microbiological  diagnoses  of  IE  were  sim-
lar  in  the  surgical  and  PPVI  patients.  History  of  IE  is  a  major
isk  factor  for  the  development  of  future  IE  in  both  groups.
t  is  important  to  note  that  despite  a  higher  incidence  of
elody  valve  IE,  probabilities  of  survival  and  event-free  sur-
ival  were  similar  to  those  in  the  surgical  group.
roposed hypothesis for percutaneous
ulmonary valve infective endocarditis
nd  possible pathogenesis
he  development  of  PPV  IE  is  probably  multifactorial,
lthough  intrinsic  characteristics  of  the  bovine  jugular  vein
ppear  to  play  a  role  in  IE,  as  we  found  a  similar  rate  of  IE
n  surgical  (Contegra)  and  transcatheter  (Melody)  implants.As  transient  bacteraemia  is  noted  every  day  during
rushing,  straining  etc.,  and  as  there  are  no  data  on  the  rela-
ionship  between  IE  and  the  dose  of  bacteria  injected  during
hysiological/pathological  invasion,  we  are  compelled  to
b
a
sM.  Patel  et  al.
hink  of  factors  other  than  traditional  invasive  procedures  as
isk  factors  for  IE.  This  may  support  bovine  tissue  immuno-
ogical  characteristics,  which  may  cause  an  idiosyncratic
eaction  after  implantation,  favouring  the  formation  of  non-
acterial  thrombotic  endocarditis  as  the  ﬁrst  step  towards
PV  IE.  Incomplete  opening  of  the  RVOT  conduit  during
PVI,  with  resultant  residual  gradient,  may  be  an  important
nciting  factor,  disrupting  laminar  ﬂow  and  causing  eccen-
ric  turbulence,  endocardial  injury  and  thrombus  formation.
he  striking  similarity  between  the  behaviour  of  the  Conte-
ra  and  Melody  valves  supports  this  hypothesis.  Thrombus
ormation  has  been  seen  to  occur  with  Contegra  conduits
sed  in  various  surgical  situations  [29—31].  We  also  noted
hat  three  of  four  patients  in  our  series  had  abruptly  dis-
ontinued  aspirin,  which  favours  the  thrombotic  hypothesis.
he  voluminous  thrombus  and  ﬁbrin  strands  with  amorphous
aterial  noted  in  all  the  vegetations  suggest  that  throm-
otic  obstruction  is  an  important  and  possibly  an  initial  step
n  the  pathogenesis.  The  severity  of  the  clinical  presenta-
ion  is  clearly  related  to  the  acute  and  severe  obstruction
f  the  RVOT  [22]. Although  commensals  have  been  reported
o  be  the  causative  organisms,  the  delay  between  PPVI  and
E  makes  the  possibility  of  hospital  acquisition  of  infection
uring  implantation  very  unlikely.  It  is  possible  that  there
s  enhanced  tropism  of  microbes  to  the  bovine  jugular  vein,
lthough  in  vitro  studies  may  be  required  to  establish  this
ypothesis.  Fig.  4  shows  a  schematic  representation  of  the
roposed  hypothesis  for  PPV  IE.
The  role  of  platelet  clumping  as  the  initial  pathogenetic
echanism  for  non-bacterial  thrombotic  endocarditis  has
een  described.  The  severity  of  endocarditis,  with  acute
r  chronic  use  of  antiplatelets  reducing  the  need  for  acute
alve  replacement  and  overall  mortality,  has  been  described
xtensively  in  in  vitro  and  in  vivo  studies  [39].  However,  to
he  best  of  our  knowledge,  there  are  no  data  showing  that
ntiplatelet  therapy  prevents  endocarditis.
In patients  with  synthetic  conduits  as  the  RVOT  substrate
nd  landing  zone  for  the  Melody  valve,  a  striking  absence
f  or  incomplete  endothelialization  was  noted  (Fig.  2).
his  raises  important  questions  about  the  need  for  more
obust  anticoagulation,  with  either  traditional  oral  anti-
oagulants/newer  oral  anticoagulants  or  dual  antiplatelet
herapy  [39].
Although  there  are  no  reports  of  IE  so  far  with  the
dwards  SAPIENTM valve  in  the  pulmonary  position,  we  are
ware  of  multiple  unreported  cases  (two  in  the  initial  series
f  64  patients;  oral  presentation  at  the  Paediatric  and  Adult
nterventional  Cardiac  Symposium,  2014).  Moreover,  reports
f  endocarditis  in  transcatheter  aortic  valve  implantation,
hich  constitutes  the  same  pericardial  substrate,  are  up  to
.4%  at  one  year,  with  a  person-time  incidence  rate  of  2.99%
er  patient  year,  which  is  very  similar  to  what  is  reported
ith  the  Melody  valve  [40].
There  is  evidence  to  suggest  that  any  instrumentation
n  the  percutaneous  valve  during  preparation,  implanta-
ion  and  even  postdilatation  balloon  injury  may  cause  tissue
njury  and  might  favour  thrombus  formation  and  the  seeding
f  microorganisms  [41,42].  Such  in  vitro  studies  have  only
een  done  with  pericardial  valves.  No  data  are  presently
vailable  for  the  Melody  valve.
It  is  possible  that  putative  xenogeneic  antigens  may  elicit
ome  degree  of  immune  response  in  the  Melody  valve.
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thrombotic endocarditis; PV: pulmonary valve; RVOT: right ventricu
However,  little  is  known  about  the  nature  and  identity
of  bovine  proteins  eliciting  destructive  or  non-destructive
immune  responses.  A  variety  of  functional  and  structural
protein  types,  including  both  cellular  and  extracellular  pro-
teins,  may  be  implicated  [43,44].
Prevention
As  only  a  few  cases  have  been  reported  in  the  literature,
it  is  hard  to  identify  predictors  and  deﬁnitive  risk  fac-
tors  for  PPV  IE.  History  of  endocarditis,  male  sex,  multiple
stents,  dental  treatment,  previous  fungal  infection,  tat-
too,  septic  wound  and  abrupt  discontinuation  of  aspirin,
among  others,  have  been  reported  as  possible  risk  factors
[21—28,45—49].  Worsening  RVOT  obstruction  is  a  dominant
ﬁnding  in  most  patients.  Buber  et  al.  proposed  life-long  pre-
procedural  antibiotics  for  PPVI  patients  with  either  a  history
of  previous  IE  or  a  complex  RVOT  anatomy  [23].  We  feel  that
the  core  IE  committee  should  convene  to  reframe  the  guide-
lines  for  PPV  IE.  It  is  hard  to  predict  whether  modiﬁcation
e
n
I
Ilmonary valve infective endocarditis (PPV IE). NBTE: non-bacterial
utﬂow tract.
f  the  existing  structure  of  Melody  valve  to  decellularize  it
or  targeted  removal  of  xenoantigens  would  help  to  reduce
he  incidence  of  thrombus  formation  and  IE.
atient management
n  view  of  the  limited  number  of  patients,  it is  hard
o  identify  those  who  might  beneﬁt  from  a  standardized
pproach.  An  individual  approach  for  each  patient  may
e  required,  due  to  the  wide  variations  in  presentation.
t  is  important  to  determine  if  the  PPV  is  anatomically
nvolved  or  is  a  bystander,  as  the  management  algo-
ithms  would  then  change.  Urgent  intervention  to  relieve
cute  obstruction  secondary  to  direct  valve  involvement
s  likely  to  reduce  mortality  and  should  always  be  con-
idered,  along  with  aggressive  IE  management.  McElhinney
t  al.  [24]  proposed  that  Melody  valve  replacement  is
ot  required  during  the  acute  treatment  of  Melody  valve
E,  when  there  is  no  involvement  of  the  valve  system.
n  all  cases,  early  surgery  should  be  considered  for  valve
622  M.  Patel  et  al.
Figure 5. Proposed algorithm for the management of percutaneous pulmonary valve infective endocarditis. 3D: three-dimensional;
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cCE: intracardiac echocardiography; IE, infective endocarditis; PET-
entricular outﬂow tract obstruction; TOE: transoesophageal echoc
ysfunction  or  absence  of  clinical  improvement  despite
ggressive  medical  treatment.  Use  of  alternative  imag-
ng  modalities,  such  as  transoesophageal  echocardiography,
ntracardiac  echocardiography,  three-dimensional  echocar-
iography  and  positron  emission  tomography-computed
omography,  should  be  used  freely  for  suspected  IE.  Fig.  5
hows  a  schematic  representation  of  the  algorithm  we  pro-
ose  for  the  management  of  PPV  IE.
edo melody after percutaneous pulmonary
alve infective endocarditis
PV  IE  seems  to  defeat  a  lot  of  traditional  thought  pro-
esses  in  IE.  Although  a  history  of  endocarditis  is  a  known
isk  factor  for  new/repeat  IE  in  a  surgical  patient,  for  rea-
ons  not  known  we  did  not  ﬁnd  an  increased  risk  of  repeat
E  in  patients  who  received  the  Melody  valve.  In  patients
ith  a  history  of  IE,  our  protocol  is  to  implant  the  Melody
alve  after  a  minimum  of  one  year  of  clinical  and  bacte-
iological  cure.  We  follow  the  same  protocol  for  patients
ith  Melody  valve  IE  without  haemodynamic  compromise
nd  after  successful  treatment  with  antibiotics.
p
o
p
Positron emission tomography-computed tomography; RVOTO: right
graphy.
rognosis
he  published  reports  and  studies  show  an  overall  mortal-
ty  rate  of  13%  in  association  with  PPV  IE.  Over  half  of
he  patients  reported  underwent  bioprosthesis  explantation
24]. In  our  cohort,  PPV  IE  signiﬁcantly  affected  survival.
onclusions
he  rising  incidence  of  PPV  IE,  its  unpredictable  clinical
ourse  and  the  associated  poor  outcomes  raise  serious
afety  concerns.  The  overall  epidemiology  of  IE  has  shown
 dynamic  trend  due  to  increased  antibiotic  use,  the  emer-
ence  of  resistant  microorganisms  and  the  increased  use
f  cardiovascular  devices,  including  percutaneous  valves.
he  2007  American  College  of  Cardiology/American  Heart
ssociation  prevention  and  treatment  guidelines  are  more
omprehensive,  making  management  easier  for  the  treating
hysician.  However,  if  the  atypical  and  unnatural  history
f  PPV  IE  is  not  anticipated,  it  could  lead  to  a  stormy  and
otentially  fatal  outcome.  The  data  published  so  far  on
PV  IE  are  gathered  from  case  series  and  a limited  number
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[Melody  valve  endocarditis  
of  patients  from  registries.  We  need  more  data  from
multicentre  studies  or  global  registries  to  identify  the  true
incidence  and  annual  risk  of  PPV  IE  in  such  patients.  Tissue
diagnosis  along  with  immunohistochemical  staining  may
help  us  to  understand  the  underlying  pathophysiology.  There
seems  to  be  a  striking  similarity  between  the  Contegra  and
Melody  valves  with  respect  to  its  common  origin,  in  vivo
characteristics  for  thrombus  formation  and  risk  of  IE.  Any
degree  of  rise  in  RVOT  gradient  during  follow-up,  along  with
other  subtle  signs,  as  described—even  in  an  asymptomatic
patient—should  not  be  ignored.  Further  data  are  required
to  identify  deﬁnitively  who  would  beneﬁt  from  antibiotic
therapy  alone,  without  surgery  or  with  another  PPV,  in  the
setting  of  PPV  IE.  It  is  important  to  identify  if  the  valve  is
directly  involved  or  if  it  is  a  bystander  to  near  or  remote
IE.  Urgent  intervention  to  relieve  acute  obstruction  is
likely  to  reduce  mortality  and  should  always  be  considered
along  with  aggressive  IE  management.  Strict  life-long
aspirin  treatment  and  IE  prophylaxis  must  be  followed
in  all  cases  during  transcatheter  insertion  of  the  Melody
valve  and  thereafter,  even  for  low-risk  invasive  procedures.
An  extensive  preprocedure  infectious  disease  evaluation
must  be  done  in  all  patients,  in  search  of  possible  port
of  entry  for  microorganisms,  similar  to  the  preoperative
evaluation  before  surgical  valve  replacement.  Multicentre
studies  are  needed  to  pool  larger  numbers  of  patients  and
identify  strong  predictors  of  IE  in  this  population.  Additional
input  from  studies  on  other  transcatheter  heart  valves  may
answer  the  question  about  the  percutaneous  approach  being
a  possible  risk  factor,  along  with  other  prosthetic  material-
based  substrates  as  potential  risk  factors.  Most  importantly,
there  is  an  immediate  need  to  address  the  prevention  and
treatment  guidelines  for  percutaneous  valve  IE.
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